Siemens Healthineers ( (SEMHF) ) has released its Q3 earnings. Here is a breakdown of the information Siemens Healthineers presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Siemens Healthineers is a leading global medical technology company specializing in imaging, diagnostics, and advanced therapies, with a focus on healthcare innovations that improve patient outcomes worldwide.
In its third quarter of fiscal year 2025, Siemens Healthineers reported significant revenue growth and increased profitability, driven by strong performances in its Imaging and Varian segments, despite challenges in the Diagnostics segment.
The company achieved a 7.6% increase in comparable revenue, reaching nearly €5.7 billion, with notable contributions from the Imaging segment, which saw an 11.7% growth, and the Varian segment, which grew by 8.7%. The adjusted EBIT margin improved to 16.8%, and free cash flow surged by over 50% to €844 million. Adjusted basic earnings per share rose to €0.64, reflecting a 23% increase from the previous year.
Despite a slight decline in the Diagnostics segment revenue, the company benefited from cost reductions and a favorable business mix. The Advanced Therapies segment also saw a modest revenue increase of 4.5%. Geographically, the Americas and Asia Pacific Japan regions experienced strong revenue growth, while the EMEA region posted a slight increase.
Looking ahead, Siemens Healthineers has updated its fiscal year 2025 outlook, anticipating a comparable revenue growth of 5.5% to 6% and adjusted basic earnings per share between €2.30 and €2.45, reflecting confidence in its continued performance amidst geopolitical uncertainties.